筋萎縮性側索硬化症の世界市場

筋萎縮性側索硬化症の世界市場は2030年に32億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に7億7,280万米ドルと推定される筋萎縮性側索硬化症の世界市場は、2030年には32億米ドルの改定規模に達し、2022年から2030年にかけて19.3%のCAGRで成長すると予測されます。

米国市場は2億3,540万米ドル、中国はCAGR18.4%で成長すると予測される

米国の筋萎縮性側索硬化症市場は、2022年に2億3,540万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが18.4％となり、2030年には5億3,450万米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ17.2％と16.5％の成長が予測されています。欧州では、ドイツがCAGR14.2%で成長すると予測されています。

調査対象企業の例

• AB Science SA
• Apotex, Inc.
• Aquestive
• Biogen, Inc.
• Brainstorm Cell Therapeutics Inc.
• Cytokinetics, Inc.
• F. Hoffmann-La Roche AG
• Genervon Biopharmaceuticals LLC
• Ionis Pharmaceuticals, Inc.
• Kringle Pharma Inc.
• Mitsubishi Tanabe Pharma Corporation
• Neuralstem, Inc.
• Orion Corporation
• Orphazyme A/S
• Sanofi SA
• Treeway BV
• Valeant Pharmaceuticals International, Inc.
• ViroMed Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• 世界のその他の地域

第4章 競合

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Amyotrophic Lateral Sclerosis Market to Reach $3.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Amyotrophic Lateral Sclerosis estimated at US$772.8 Million in the year 2022, is projected to reach a revised size of US$3.2 Billion by 2030, growing at a CAGR of 19.3% over the period 2022-2030.

The U.S. Market is Estimated at $235.4 Million, While China is Forecast to Grow at 18.4% CAGR

The Amyotrophic Lateral Sclerosis market in the U.S. is estimated at US$235.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$534.5 Million by the year 2030 trailing a CAGR of 18.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.2% and 16.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.2% CAGR.

Select Competitors (Total 23 Featured) -

• AB Science SA
• Apotex, Inc.
• Aquestive
• Biogen, Inc.
• Brainstorm Cell Therapeutics Inc.
• Cytokinetics, Inc.
• F. Hoffmann-La Roche AG
• Genervon Biopharmaceuticals LLC
• Ionis Pharmaceuticals, Inc.
• Kringle Pharma Inc.
• Mitsubishi Tanabe Pharma Corporation
• Neuralstem, Inc.
• Orion Corporation
• Orphazyme A/S
• Sanofi SA
• Treeway BV
• Valeant Pharmaceuticals International, Inc.
• ViroMed Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Amyotrophic Lateral Sclerosis - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 3: World 16-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • TABLE 4: World Amyotrophic Lateral Sclerosis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • TABLE 5: USA Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 6: USA Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• CANADA
  • TABLE 7: Canada Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 8: Canada Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• JAPAN
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • TABLE 9: Japan Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 10: Japan Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• CHINA
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • TABLE 11: China Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 12: China Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• EUROPE
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • TABLE 13: Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 14: Europe Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • TABLE 15: Europe 16-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
• FRANCE
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • TABLE 16: France Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 17: France Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• GERMANY
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • TABLE 18: Germany Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 19: Germany Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• ITALY
  • TABLE 20: Italy Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 21: Italy Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• UNITED KINGDOM
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • TABLE 22: UK Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 23: UK Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• REST OF EUROPE
  • TABLE 24: Rest of Europe Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 25: Rest of Europe Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• ASIA-PACIFIC
  • Amyotrophic Lateral Sclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 27: Asia-Pacific Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
• REST OF WORLD
  • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 29: Rest of World Historic Review for Amyotrophic Lateral Sclerosis by Segment - Amyotrophic Lateral Sclerosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

IV. COMPETITION